A relationship of serum imunoglobulin free light chain levels measurement to multiple myeloma staging

Česká verze

Authors: T. Pika ¹; M. Zemanová ¹; J. Minařík ¹; P. Schneiderka ²; J. Bačovský ¹; V. Ščudla ¹
Authors place of work: III. interní klinika LF UP a FN, Olomouc ; Oddělení klinické biochemie FN, Olomouc ²
Published in the journal: Transfuze Hematol. dnes,13, 2007, No. 1, p. 12-15.
Category: Souhrnné práce, původní práce, kazuistiky

Summary

The study is aimed to evaluate of serum imunoglobulin free light chain levels measurement in multiple myeloma and their relationship to each stage not only of traditional Durie –⁠ Salmon staging system, but also to recently established International Staging System and South West Oncology Group staging system. The results of analysis showed that serum free light chain levels corelate with each stage of staging systems based on dynamic indices (serum albumin and ß2-microglobulin) more expressively, than traditional Durie –Salmon staging system. The study also confirmed dependency of serum free light chain levels upon renal function.

Key words:
imunoglobulin free light chains, multiple myeloma, staging systems

Zdroje

1. Malpas JS, Cavenagh JD. Clinical presentation, laboratory diagnosis, and indications for treatment. In: Malpas JS, Bergsagel DE, Kyle RA, et al. Myeloma Biology and Management. 3rd edit. Philadelphia: Saunders 2004 : 159–173.

2. Adam Z, Hájek R, Mayer J, et al. Mnohočetný myelom a další monoklonální gamapatie. 1. vyd. Brno: Lékařská fakulta Masarykovy univerzity 1999; 357 s.

3. Lokhorst H. Clinical features and diagnostic criteria. In: Mehta J, Singhal S. Myeloma. 1st edit. London: Martin Dunitz Ltd 2002 : 151–168.

4. Bradwell AR. Serum Free Light Chain Analysis. 2nd edit. Birmingham: The Binding Site Ltd. 2004.

5. Engliš M. Stanovení volných lehkých řetězců imunoglobulinů v séru v diagnostice a monitorování monoklonálních gamapatií. http://www.cskb.cz/vzdelavani/light_chain.htm

6. Alyanakian MA, Abbas A, Delarue R, et al. Free Immunoglobulin light chains serum levels in the follow-up of patiens with monoclonal gammopathies: correlation with the 24H urinary light-chain excretion. Clin Chem 2003; 49 (Suppl.6): A105, D-54.

7. Mead GP, Carr-Smith HD, Drayson MT, et al. Serum free light chain levels in patients with intact imunoglobulin myeloma. Clin Chem 2002; 49 (Suppl 6): A 107.

8. Bradwell AR, et al. Management of patients with light chain myeloma using serum free light chain immunoassays. Clin Chem 2002; 48 (Suppl. 6): A 51.

9. Ščudla V, Vytřasová M, Minařík J. Klinický význam hodnocení sérových hladin volných lehkých řetězců imunoglobulinu u monoklonálních gamapatií. Trans Hemat dnes 2005; 11 : 47–53.

10. Ščudla V, Minařík J, Schneiderka P, et al. Význam sérových hladin volných lehkých řetězců imunoglobulinu v diagnostice a hodnocení aktivity mnohočetného myelomu a vybraných monoklonálních gamapatií. Vnitř Lék 2005; 11 : 1249–1259.

11. Nowrousian MR, et al. Using serum free light chain assays in the Myeloma Clinic. In Bradwell A.R. Serum Free Light Chain Analysis. 3rd edit. Birmingham: The Binding Site Ltd. 2005.

12. Mead GP, Carr-Smith HD, Drayson MT, et al. Serum free light chains for monitoring multiple myeloma. Brit J Haematol 2004; 126 : 348–354.

13. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Cancer 1975; 36 : 824–854.

14. Greipp PR, San Miguel JF, Fonseca R, et al. Development of an International prognostic index (IPI) for myeloma: report of the internatiomal myeloma group. Hemat J 2003; 4 (Suppl 1): S42–43.

15. Greipp PR, San Miguel J, Durie BGM, et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23 : 3412–3420.

16. Jacobson JL, Hussein MA, Barlogie B, et al. A new staging system for multiple myeloma pacients based on the Southwest Oncology Group (SWOG) experience. Brit J Hemat 2003; 122 : 441–450.

17. Hérnandez J, Olivier O, Fisac R, et al. Comparison of the internatiomal prognostic index and Durie –⁠ Salmon staging system to detect differences in the levels of biochemical markers of bone remodeling and serum cytokines in multiple myeloma. Hemat J 2005; 90 : 97.

18. Wang M, Alexanian R, Delasalle KB, et al. Confirmation of the prognostic value of international staging system for multiple myeloma proposed by the International myeloma working group and South west oncology group staging system with similar results using beta2microglobulin alone. Hemat J 2005; 90 : 97.